These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31004381)

  • 1. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
    Chen J; Liu H; Li L; Liu Z; Song J; Wang G; Wang H; Ruan E; Ding K; Shao Z; Fu R
    J Clin Lab Anal; 2019 Jun; 33(5):e22888. PubMed ID: 31004381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
    Dimopoulos MA; Delimpasi S; Katodritou E; Vassou A; Kyrtsonis MC; Repousis P; Kartasis Z; Parcharidou A; Michael M; Michalis E; Gika D; Symeonidis A; Pouli A; Konstantopoulos K; Terpos E; Kastritis E
    Ann Oncol; 2014 Jan; 25(1):195-200. PubMed ID: 24356630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
    An N; Li X; Shen M; Chen SL; Huang ZX
    Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.
    Chen X; Luo X; Zu Y; Issa HA; Li L; Ye H; Yang T; Hu J; Wei L
    J Clin Lab Anal; 2020 Sep; 34(9):e23416. PubMed ID: 32710448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
    Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
    Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
    Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
    Eleftherakis-Papapiakovou E; Kastritis E; Roussou M; Gkotzamanidou M; Grapsa I; Psimenou E; Nikitas N; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2011 Dec; 52(12):2299-303. PubMed ID: 22141916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
    Xu Y; An G; Deng SH; Sui WW; Feng XY; Li F; Hao M; Wang YF; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):304-8. PubMed ID: 23668201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
    Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
    Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
    Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
    Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
    PLoS One; 2014; 9(7):e101819. PubMed ID: 25003848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of bortezomib for treating multiple myeloma with renal impairment].
    Kang Y; Zhao YY; Guo M; Yu CL; Qiao JH; Hu KX; Sun QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):628-31. PubMed ID: 22739170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
    Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Characteristic, Prognosis and Treatment Outcome of Elderly Multiple Myeloma Patients with Impaired Renal Function].
    Fan L; Ma YP; Chao Y; Gao XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):145-151. PubMed ID: 33554811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
    Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
    Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.